当前位置: 首页 >> 检索结果
1041. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
作者: Darrell S Pardi.;Edward V Loftus.;Walter K Kremers.;Jill Keach.;Keith D Lindor.
来源: Gastroenterology. 2003年124卷4期889-93页
Ursodeoxycholic acid (UDCA) has shown effectiveness as a colon cancer chemopreventive agent in preclinical studies. In addition, a recent report suggests that it also may decrease the risk for developing colorectal dysplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We sought to evaluate the effect of UDCA on colorectal neoplasia in a group of patients with UC and PSC enrolled in a randomized, placebo-controlled trial.
1042. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.
作者: Ralf Kiesslich.;Johannes Fritsch.;Martin Holtmann.;Heinz H Koehler.;Manfred Stolte.;Stephan Kanzler.;Bernhard Nafe.;Michael Jung.;Peter R Galle.;Markus F Neurath.
来源: Gastroenterology. 2003年124卷4期880-8页
Timely diagnosis of intraepithelial neoplasias (IN) and colitis-associated colon carcinomas (CRC) is crucially important for the treatment of ulcerative colitis (UC). We performed a randomized, controlled trial to test whether chromoendoscopy (CE) might facilitate early detection of IN and CRC in UC.
1043. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
作者: Didier Samuel.;Thierry Bizollon.;Cyrille Feray.;Bruno Roche.;Si Nafa Si Ahmed.;Catherine Lemonnier.;Marielle Cohard.;Michel Reynes.;Michelle Chevallier.;Christian Ducerf.;Jacques Baulieux.;Michael Geffner.;Janice K Albrecht.;Henri Bismuth.;Christian Trepo.
来源: Gastroenterology. 2003年124卷3期642-50页
Hepatitis C virus (HCV) reinfection after liver transplantation is frequent and leads to chronic hepatitis and cirrhosis. The use of antiviral therapy in this situation remains controversial. This study aimed to assess the safety and efficacy of interferon alfa-2b plus ribavirin for recurrent hepatitis C following liver transplantation.
1044. The North American Study for the Treatment of Refractory Ascites.
作者: Arun J Sanyal.;Chris Genning.;K Rajender Reddy.;Florence Wong.;Kris V Kowdley.;Kent Benner.;Timothy McCashland.; .
来源: Gastroenterology. 2003年124卷3期634-41页
The clinical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-à-vis total paracentesis in the management of refractory ascites is unclear.
1045. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study.
作者: Stefano Fiorucci.;Luca Santucci.;Paolo Gresele.;Roberto Maffei Faccino.;Piero Del Soldato.;Antonio Morelli.
来源: Gastroenterology. 2003年124卷3期600-7页
NCX-4016 is a nitric oxide-releasing derivative of aspirin with antiplatelet activity. The aim of this study was to investigate the effect of NCX-4016 on gastrointestinal mucosa and platelet functions in healthy human volunteers.
1046. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.
作者: Francis Creed.;Lakshmi Fernandes.;Elspeth Guthrie.;Stephen Palmer.;Joy Ratcliffe.;Nicholas Read.;Christine Rigby.;David Thompson.;Barbara Tomenson.; .
来源: Gastroenterology. 2003年124卷2期303-17页
Psychotherapy and antidepressants are effective in patients with severe irritable bowel syndrome (IBS), but the cost-effectiveness of either treatment in routine practice has not been established.
1047. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study.
作者: David Seguy.;Kouroche Vahedi.;Nathalie Kapel.;Jean-Claude Souberbielle.;Bernard Messing.
来源: Gastroenterology. 2003年124卷2期293-302页
Controversy surrounds a 3-week treatment with a high-dose (0.14 mg. kg(-1). day(-1)) growth hormone (GH), glutamine, and high carbohydrate diet in home parenteral nutrition (HPN)-dependent patients with short-bowel syndrome (SBS). This study assessed treatment with low-dose GH in these patients.
1048. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
作者: Loren Laine.;Laurine G Connors.;Alise Reicin.;Christopher J Hawkey.;Ruben Burgos-Vargas.;Thomas J Schnitzer.;Qinfen Yu.;Claire Bombardier.
来源: Gastroenterology. 2003年124卷2期288-92页
Epidemiologic studies suggest nonsteroidal anti-inflammatory drugs (NSAIDs) increase the risk for lower gastrointestinal (GI) clinical events, but data from prospective trials are lacking. Cyclooxygenase (COX)-2-selective inhibitors decrease upper GI clinical events but the effect on lower GI events has not been determined. We performed a post hoc analysis of serious lower GI clinical events with a nonselective NSAID and a COX-2-selective agent in a prospective, double-blind, randomized GI outcomes trial.
1049. Histological outcome during long-term lamivudine therapy.
作者: Jules L Dienstag.;Robert D Goldin.;E Jenny Heathcote.;H W L Hann.;Mary Woessner.;Sally L Stephenson.;Stephen Gardner.;D Fraser Gray.;Eugene R Schiff.
来源: Gastroenterology. 2003年124卷1期105-17页
One year of lamivudine for chronic hepatitis B results in histologic improvement. We aimed to assess the histological impact of longer-term treatment.
1050. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans.
作者: Sanchoy Sarkar.;Anthony R Hobson.;Andrew Hughes.;Jim Growcott.;Clifford J Woolf.;David G Thompson.;Qasim Aziz.
来源: Gastroenterology. 2003年124卷1期18-25页
Central sensitization, an activity-dependent increase in spinal cord neuronal excitability, has been shown to contribute to esophageal pain hypersensitivity. Prostaglandin E2 (PGE(2)) is a mediator in both peripheral and central sensitization, in part via the prostaglandin E2 receptor-1 (EP-1), and may be a potential target for treating visceral pain. The purpose of this study was to determine whether acid-induced pain hypersensitivity within the non-acid-exposed esophagus (secondary hyperalgesia) is mediated by PGE(2) activation of the EP-1 receptor.
1051. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.
作者: José M Sánchez-Tapias.;Josep Costa.;Antoni Mas.;Miquel Bruguera.;Juan Rodés.
来源: Gastroenterology. 2002年123卷6期1848-56页
The aim of this study was to investigate if the variable outcome of chronic hepatitis B may be related to hepatitis B virus (HBV) genotype.
1052. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
作者: Pere Ginès.;Juan Uriz.;Blas Calahorra.;Guadalupe Garcia-Tsao.;Patrick S Kamath.;Luis Ruiz Del Arbol.;Ramón Planas.;Jaime Bosch.;Vicente Arroyo.;Juan Rodés.
来源: Gastroenterology. 2002年123卷6期1839-47页
The transjugular intrahepatic portosystemic shunt (TIPS) has been shown to be more effective than repeated paracentesis plus albumin in the control of refractory ascites. However, its effect on survival and healthcare costs is still uncertain.
1053. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
作者: Ching-Lung Lai.;Mohamed Rosmawati.;Judy Lao.;Hans Van Vlierberghe.;Frank H Anderson.;Neal Thomas.;Deborah Dehertogh.
来源: Gastroenterology. 2002年123卷6期1831-8页
Entecavir is a novel and selective nucleoside analogue with potent activity against hepatitis B virus (HBV).
1054. Long-term improvement in functional dyspepsia using hypnotherapy.
作者: Emma Louise Calvert.;Lesley Anne Houghton.;Patricia Cooper.;Julie Morris.;Peter James Whorwell.
来源: Gastroenterology. 2002年123卷6期1778-85页
We have shown hypnotherapy (HT) to be effective in irritable bowel syndrome, with long-term improvements in symptomatology and quality of life (QOL). This study aimed to assess the efficacy of HT in functional dyspepsia (FD).
1055. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study.
作者: Peter H Katelaris.;Geoffrey M Forbes.;Nicholas J Talley.;Brendan Crotty.
来源: Gastroenterology. 2002年123卷6期1763-9页
Direct comparisons of bismuth and proton pump inhibitor (PPI)-based triple and quadruple therapies for Helicobacter pylori eradication are lacking. To address this, a randomized study was conducted.
1056. Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?
作者: Gerald Holtmann.;Juergen Gschossmann.;Lydia Buenger.;Guido Gerken.;Nicholas J Talley.
来源: Gastroenterology. 2002年123卷5期1451-8页
We hypothesized that the development of dyspeptic symptoms during treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) would be linked to alterations in gastric mechanosensory function and gastric emptying.
1057. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
作者: Sanaa M Kamal.;Jutta Fehr.;Bernd Roesler.;Thomas Peters.;Jens W Rasenack.
来源: Gastroenterology. 2002年123卷4期1070-83页
Pegylated interferons (IFNs) with or without ribavirin were shown in several studies to improve sustained virologic response compared with standard IFN alpha-2 therapy. This study investigated if the greater efficacy of pegylated IFNs might be related to modulation of immunologic responses.
1058. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.
作者: D Patch.;C A Sabin.;J Goulis.;G Gerunda.;L Greenslade.;C Merkel.;A K Burroughs.
来源: Gastroenterology. 2002年123卷4期1013-9页
Patients who have had one variceal bleed are at high risk of rebleeding. Since its introduction, endoscopic variceal banding has been shown to be superior to needle sclerotherapy. Banding has not been compared with hepatic venous pressure-guided medical therapy (beta-blockers and nitrates).
1059. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
作者: Loren Laine.;Claire Bombardier.;Christopher J Hawkey.;Barry Davis.;Deborah Shapiro.;Christopher Brett.;Alise Reicin.
来源: Gastroenterology. 2002年123卷4期1006-12页
Epidemiologic data indicate that the risk of nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal (GI) clinical events varies based on patients' clinical characteristics. The authors determined risk factors for NSAID-related clinical upper GI events and the event rates, absolute risk reductions, and numbers needed to treat for individual risk factors for a nonselective NSAID and a selective cyclooxygenase 2 inhibitor in a double-blind outcomes trial.
1060. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease.
作者: Guido Costamagna.;Saumil K Shah.;Maria Elena Riccioni.;Francesca Foschia.;Massimiliano Mutignani.;Vincenzo Perri.;Amorino Vecchioli.;Maria Gabriella Brizi.;Aurelio Picciocchi.;Pasquale Marano.
来源: Gastroenterology. 2002年123卷4期999-1005页
This study was undertaken to prospectively compare the clinical outcomes of small bowel radiographs with the wireless capsule endoscopy.
|